Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$1.50 -4.5%	$2.22	$1.11 ▼ $5.00	$417.84M	1.9	2.84 million shs	2.14 million shs
CGEM Cullinan Therapeutics	$7.54 -0.9%	$7.74	$6.85 ▼ $19.89	$449.56M	-0.08	360,653 shs	285,302 shs
DNTH Dianthus Therapeutics	$23.57 -5.0%	$20.60	$13.36 ▼ $32.27	$798.59M	1.43	382,629 shs	345,906 shs
FTLF FitLife Brands	$18.62 -0.3%	$14.50	$9.83 ▼ $18.96	$175.43M	0.79	22,174 shs	11,216 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	-4.46%	-14.29%	-39.76%	-13.79%	-61.73%
CGEM Cullinan Therapeutics	-0.92%	-7.94%	-7.60%	-12.93%	-59.68%
DNTH Dianthus Therapeutics	-5.00%	-3.00%	+13.32%	+35.30%	-16.98%
FTLF FitLife Brands	-0.32%	+9.53%	+49.80%	+25.47%	+12.20%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUTL Autolus Therapeutics	2.7123 of 5 stars	3.5	1.0	3.0	3.3	0.6
CGEM Cullinan Therapeutics	1.9209 of 5 stars	3.5	0.0	2.9	1.7	0.6
DNTH Dianthus Therapeutics	1.1475 of 5 stars	3.5	0.0	1.9	0.8	0.0
FTLF FitLife Brands	3.5022 of 5 stars	2.5	4.0	2.7	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUTL Autolus Therapeutics	3.00	Buy	$9.12	508.00% Upside
CGEM Cullinan Therapeutics	3.00	Buy	$26.80	255.44% Upside
DNTH Dianthus Therapeutics	3.00	Buy	$54.00	129.10% Upside
FTLF FitLife Brands	3.00	Buy	$22.00	18.15% Upside

Current Analyst Ratings Breakdown

Latest FTLF, CGEM, DNTH, and AUTL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	CGEM Cullinan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$24.00
8/21/2025	DNTH Dianthus Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$34.00 ➝ $42.00
8/18/2025	CGEM Cullinan Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$35.00 ➝ $28.00
8/15/2025	FTLF FitLife Brands	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $25.00
8/13/2025	AUTL Autolus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$6.00 ➝ $5.00
7/21/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
7/2/2025	DNTH Dianthus Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
6/12/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/11/2025	CGEM Cullinan Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$22.00

(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUTL Autolus Therapeutics	$10.12M	39.45	N/A	N/A	$1.30 per share	1.15
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	$8.33 per share	N/A
DNTH Dianthus Therapeutics	$6.24M	121.59	N/A	N/A	$9.42 per share	2.50
FTLF FitLife Brands	$64.47M	2.71	$1.01 per share	18.44	$4.36 per share	4.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUTL Autolus Therapeutics	-$220.66M	-$0.84	N/A	N/A	N/A	N/A	-56.18%	-29.61%	11/11/2025 (Estimated)
CGEM Cullinan Therapeutics	-$167.38M	-$3.23	N/A	N/A	N/A	N/A	-36.56%	-34.82%	11/6/2025 (Estimated)
DNTH Dianthus Therapeutics	-$84.97M	-$3.25	N/A	N/A	N/A	-2,364.56%	-34.72%	-32.72%	11/6/2025 (Estimated)
FTLF FitLife Brands	$8.98M	$0.84	22.17	16.93	N/A	12.63%	21.70%	13.45%	N/A

Latest FTLF, CGEM, DNTH, and AUTL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	FTLF FitLife Brands	$0.18	$0.18	N/A	$0.18	$16.17 million	$16.13 million
8/12/2025	Q2 2025	AUTL Autolus Therapeutics	-$0.24	-$0.18	+$0.06	-$0.18	$12.92 million	$13.50 million
8/7/2025	Q2 2025	CGEM Cullinan Therapeutics	-$0.83	-$1.07	-$0.24	-$1.07	N/A	N/A
8/7/2025	Q2 2025	DNTH Dianthus Therapeutics	-$0.86	-$0.88	-$0.02	-$0.88	$0.87 million	$0.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
FTLF FitLife Brands	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUTL Autolus Therapeutics	N/A	8.43	8.07
CGEM Cullinan Therapeutics	N/A	9.83	9.83
DNTH Dianthus Therapeutics	N/A	13.12	13.12
FTLF FitLife Brands	0.15	1.71	0.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUTL Autolus Therapeutics	72.83%
CGEM Cullinan Therapeutics	86.31%
DNTH Dianthus Therapeutics	47.53%
FTLF FitLife Brands	2.32%

Insider Ownership

Company	Insider Ownership
AUTL Autolus Therapeutics	25.70%
CGEM Cullinan Therapeutics	7.16%
DNTH Dianthus Therapeutics	8.15%
FTLF FitLife Brands	61.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUTL Autolus Therapeutics	330	266.14 million	197.74 million	Optionable
CGEM Cullinan Therapeutics	30	59.07 million	54.84 million	Optionable
DNTH Dianthus Therapeutics	80	32.19 million	29.57 million	Optionable
FTLF FitLife Brands	20	9.39 million	3.63 million	Not Optionable

FTLF, CGEM, DNTH, and AUTL Headlines

Recent News About These Companies

Mink Brook Asset Management LLC Has $929,000 Stake in FitLife Brands Inc. $FTLF

August 26, 2025 | marketbeat.com

FitLife Brands Updates Corporate Presentation Strategy

August 20, 2025 | msn.com

Roth Capital Forecasts Strong Price Appreciation for FitLife Brands (NASDAQ:FTLF) Stock

August 17, 2025 | marketbeat.com

FitLife Brands (NASDAQ:FTLF) Issues Quarterly Earnings Results, Meets Estimates

August 16, 2025 | marketbeat.com

FitLife Brands, Inc. (NASDAQ:FTLF) Q2 2025 Earnings Call Transcript

August 16, 2025 | msn.com

FitLife Brands price target raised to $25 from $20 at Roth Capital

August 15, 2025 | msn.com

FitLife Brands Reports Q2 2025 Financial Results

August 15, 2025 | msn.com

FitLife Brands, Inc. (FTLF) Q2 2025 Earnings Call Transcript

August 14, 2025 | seekingalpha.com

FitLife Brands Holds 2025 Annual Stockholders Meeting

August 14, 2025 | msn.com

FitLife Brands Reports 5 Percent Q2 Drop

August 14, 2025 | aol.comA

FitLife Brands reports Q2 EPS 18c vs. 27c last year

August 14, 2025 | msn.com

A Peek at FitLife Brands's Future Earnings

August 13, 2025 | benzinga.com

Analysts Offer Insights on Consumer Goods Companies: Church & Dwight (CHD) and FitLife Brands (FTLF)

August 11, 2025 | theglobeandmail.com

FitLife Brands Closes Acquisition of Irwin Naturals

August 11, 2025 | globenewswire.com

Roth Capital Estimates FitLife Brands Q2 Earnings

August 9, 2025 | marketbeat.com

Roth Capital Reduces Earnings Estimates for FitLife Brands

August 8, 2025 | marketbeat.com

FitLife Brands (NASDAQ:FTLF) Trading 18.4% Higher - Here's Why

August 6, 2025 | marketbeat.com

FitLife Brands to Acquire Irwin Naturals

August 5, 2025 | globenewswire.com

FitLife Brands Announces Second Quarter Earnings Call

August 1, 2025 | globenewswire.com

FitLife Brands: Premium Valuation Faces Uncertain Rebound, A Hold For Now

July 24, 2025 | seekingalpha.com

FitLife Brands Holds on to Analyst Confidence Amid Mixed Sales and Online Strength

July 24, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTLF, CGEM, DNTH, and AUTL Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

$1.50 -0.07 (-4.46%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$1.50 +0.00 (+0.33%)

As of 08/29/2025 07:49 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Cullinan Therapeutics NASDAQ:CGEM

$7.54 -0.07 (-0.92%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$7.56 +0.02 (+0.32%)

As of 08/29/2025 07:34 PM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Dianthus Therapeutics NASDAQ:DNTH

$23.57 -1.24 (-5.00%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$23.61 +0.04 (+0.17%)

As of 08/29/2025 07:57 PM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

FitLife Brands NASDAQ:FTLF

$18.62 -0.06 (-0.32%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$18.64 +0.02 (+0.13%)

As of 08/29/2025 04:10 PM Eastern

FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time